Surfix announces an investment of €8.5M by a Dutch consortium consisting of Lionix International, Qurin Diagnostics, Photondelta and Oost NL. Surfix will use the investment to accelerate the development of its plug-and-play diagnostics platform for all sorts of point-of-core tests. The initial target applications are early cancer diagnosis, Covid-19 detection and tracing of pathogens in water for aquaculture.
Point-of-care diagnostics refers to performing molecular tests anywhere and anytime, i.e. without having to send samples to laboratories for analysis. Testing on the spot is more convenient, faster and cheaper. The availability of a quick and reliable tests would mean a huge step forward in the fight against the current and future pandemics. The ultimate goal for Surfix is to make a test that is available for the masses and at the cost of only a few euros.
Maarten Buijs, CEO of Surfix, is clearly excited about the investment: “Our drive is to bring point-of-care diagnostics to the next level. In combination with the network and experience of the two Dutch public-private organizations Oost NL and Photondelta, the leading-edge integrated photonics technology of LioniX and the medical knowledge of Qurin, the investment will allow us to take on the industrialization of our solution and clinically validate the exciting results in biomarker detection obtained to date.”.
Senior Investment Manager Tech Pieter Klinkert of Oost NL believes that the solution of Surfix supports the important ecosystem of photonic biochips and microfluidics which Oost NL acknowledges as key enabling technologies and that the company can realize a breakthrough in the field of diagnostics based on photonics.
Surfix, a StartLife alumnus, was founded as a spin-off from Wageningen University & Research and has been very successful as a provider of R&D services in the field of nano-coatings for biosensors and microfluidic devices. The company now focuses on the development and marketing of its plug-and-play diagnostics platform which can be used to detect viruses, DNA and RNA, proteins like antibodies and antigens, and other biomolecules.
p.s. You can also follow StartLife on Linkedin, Twitter or stay up to date with the latest news about and for agrifood startups, scaleups and more via the StartLife newsletter.